Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET
Company Participants
Meredith Kaya - Senior Vice President of Investor Relations and Strategic Finance
Cedric Francois - Co-Founder and Chief Executive Officer
Adam Townsend - Chief Operating Officer
Caroline Baumal - Chief Medical Officer
Tim Sullivan - Chief Financial Officer
Conference Call Participants
Jonathan Miller - Evercore
Tazeen Ahmad - Bank of America
Anupam Rama - JPMorgan
Salveen Richter - Goldman Sachs
Yigal Nochomovitz - Citigroup
Nicholas Econom - Raymond James
Phil Nadeau - TD Cowen
Katherine Wang - Jefferies
Ellie Merle - UBS
Annabel Samimy - Stifel
Douglas Tsao - H.C. Wainwright
Lachlan Hanbury-Brown - William Blair
Derek Archila - Wells Fargo
Biren Amin - Piper Sandler
Lisa Walter - RBC
Greg Harrison - Scotiabank
Graig Suvannavejh - Mizuho Securities
Laura Chico - Wedbush Securities
Operator
Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the Apellis Pharmaceuticals Third Quarter 2024 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to turn the call over to Meredith Kaya, Senior Vice President, Investor Relations & Strategic Finance. Please go ahead.
Meredith Kaya
Good morning, and thank you for joining us to discuss Apellis' third quarter 2024 financial results. With me on the call are Co-Founder and Chief Executive Officer, Dr. Cedric Francois; Chief Operating Officer, Adam Townsend; Chief Medical Officer, Dr. Caroline Baumal; and Chief Financial Officer, Tim Sullivan.
Before we begin, let me point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional detail.
Now I'll turn the call over to Cedric.
Cedric Francois
Thank you, Meredith, and thank you all for joining us this morning.
Over the past few months, we have made meaningful progress towards our long-term goals, reaching key milestones such as generating continued growth in vial demand for SYFOVRE and presenting the groundbreaking Phase III VALIANT results with EMPAVELI C3G and IC-MPGN. These data underscore the power of C3 and reinforce our belief that targeting C3 is the optimal way to treat complement-mediated diseases.
During the third quarter, commercial vial demand for SYFOVRE grew by 7% quarter-over-quarter and SYFOVRE maintained its market leadership with 84,500 commercial vials shipped to physicians.